Medication Overuse Headache

Chronische Kopfschmerzen infolge von Schmerzmittelübergebrauch (Medication Overuse Headache, MOH) gehören zu den häufigsten sekundären Kopfschmerzformen. Was als episodischer Schmerz beginnt, kann bei regelmäßiger Einnahme akuter Migränemedikamente oder Analgetika in einen chronischen Kopfschmerzen münden. Eine erfolgreiche Behandlung erfordert Aufklärung, gezielte Prophylaxe und manchmal eine Medikamentenpause.

Schlüsselwörter

Schmerzmittelübergebrauch - MOH - Migräneprophylaxe - chronische Kopfschmerzen - Medikamentenpause

• Literatur

• 1 Headache Classification Committee of the International Headache Society (IHS).. The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia 2018; 38: 1-211
• 2 Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014; 5: 87-99
• 3 Straube A, Pfaffenrath V, Ladwig KH. et al. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia 2010; 30: 207-213
• 4 GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024; 23: 344-381
• 5 Rizzoli P. Medication-overuse headache. Continuum (Minneap Minn) 2024; 30: 379-390
• 6 Lipton RB, Manack A, Ricci JA. et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache 2011; 51: 693-706
• 7 Wang SJ, Fuh JL, Lu SR. et al. Chronic daily headache in adolescents: prevalence, impact, and medication overuse. Neurology 2006; 66: 193-197
• 8 Bigal ME, Serrano D, Buse D. et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157-1168
• 9 Westergaard ML, Glumer C, Hansen EH. et al. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 2014; 155: 2005-2013
• 10 Schwedt TJ, Alam A, Reed ML. et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 2018; 19: 38
• 11 Hagen K, Linde M, Steiner TJ. et al. Risk factors for medication-overuse headache: an 11-year follow-up study. The Nord-Trondelag health studies. Pain 2012; 153: 56-61
• 12 Ashina S, Terwindt GM, Steiner TJ. et al. Medication overuse headache. Nat Rev Dis Primers 2023; 9: 5
• 13 Lampl C, Thomas H, Tassorelli C. et al. Headache, depression and anxiety: associations in the Eurolight project. J Headache Pain 2016; 17: 59
• 14 Diener HC, Holle D, Solbach K. et al. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 2016; 12: 575-583
• 15 Limmroth V, Katsarava Z, Fritsche G. et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014
• 16 Créac'h C, Radat F, Mick G. et al. One or several types of triptan overuse headaches?. Headache 2009; 49: 519-528
• 17 Radat F, Creac'h C, Swendsen JD. et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005; 25: 519-522
• 18 Grande RB, Aaseth K, Benth JS. et al. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 2011; 18: 129-137
• 19 Kristoffersen ES, Straand J, Vetvik KG. et al. Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: a pragmatic cluster-randomised controlled trial. J Neurol 2016; 263: 344-353
• 20 Lagman-Bartolome AM, Lawler V, Lay C. Headache education active-waiting directive: a program to enhance well-being during long referral wait times. Headache 2018; 58: 109-117
• 21 Rossi P, Faroni JV, Nappi G. Short-term effectiveness of simple advice as a withdrawal strategy in simple and complicated medication overuse headache. Eur J Neurol 2011; 18: 396-401
• 22 Pijpers JA, Kies DA, van Zwet EW. et al. Behavioural intervention in medication overuse headache: a concealed double-blind randomized controlled trial. Eur J Neurol 2022; 29: 1496-1504
• 23 Diener HC, Bussone G, Van Oene JC. et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-823
• 24 Silberstein SD, Lipton RB, Dodick DW. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-180
• 25 Aurora SK, Dodick DW, Turkel CC. et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803
• 26 Silberstein SD, Blumenfeld AM, Cady RK. et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331: 48-56
• 27 Pijpers JA, Kies DA, Louter MA. et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. Brain 2019; 142: 1203-1214
• 28 Diener HC, Marmura MJ, Tepper SJ. et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 2021; 61: 125-136
• 29 Blumenfeld A, Kudrow D, McAllister P. et al. Long-term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication-overuse headache. Headache 2024; 64: 738-749
• 30 Silberstein SD, Cohen JM, Seminerio MJ. et al. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 2020; 21: 114
• 31 Detke HC, Goadsby PJ, Wang S. et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018; 91: e2211-e2221
• 32 VanderPluym JH, Cheng N, Zhu Y. et al. Treatment of medication-overuse headache in children and adolescents: a systematic review. Headache 2025; 65: 1148-1159
• 33 Goadsby PJ, Friedman DI, Holle-Lee D. et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology 2024; 103: e209584
• 34 Giri S, Tronvik E, Linde M. et al. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia 2023; 43: 3331024231156922
• 35 Curone M, Tullo V, Didier HA. et al. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients. Neurol Sci 2022; 43: 5759-5761
• 36 Silvestro M, Orologio I, Sozio P. et al. No additional benefit with detoxification strategies: a real world experience in 200 patients with chronic migraine and either simple or complex MOH treated with CGRP monoclonal antibodies. Cephalalgia 2025; 45: 3331024251329808
• 37 Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006; 26: 1192-1198
• 38 Tassorelli C, Jensen R, Allena M. et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: a controlled multicentre study. Cephalalgia 2017; 37: 1115-1125
• 39 Schwedt T, Hentz J, Sahai-Srivastava S. et al. Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology 2022; 98: e1409-e1421
• 40 Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol 2004; 3: 475-483
• 41 Katsarava Z, Fritsche G, Muessig M. et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-1698
• 42 Boe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 2007; 69: 26-31
• 43 Rabe K, Pageler L, Gaul C. et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia 2013; 33: 202-207
• 44 Cevoli S, Giannini G, Favoni V. et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain 2017; 18: 56
• 45 Andrasik F, Grazzi L, Usai S. et al. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia 2010; 30: 610-614
• 46 Altieri M, Di Giambattista R, Di Clemente L. et al. Combined pharmacological and short-term psychodynamic psychotherapy for probable medication overuse headache: a pilot study. Cephalalgia 2009; 29: 293-299
• 47 Grazzi L, Sansone E, Raggi A. et al. Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. J Headache Pain 2017; 18: 15
• 48 Tepper SJ, Dodick DW, Lanteri-Minet M. et al. Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial. JAMA Neurology 2024; 81: 1140-1149